Login / Signup

Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND.

Ronald F Van VollenhovenStephen HallAlvin F WellsSebastian MeerweinYanna SongOishi TanjinatusRoy M Fleischmann
Published in: RMD open (2024)
NCT02706847.
Keyphrases
  • rheumatoid arthritis
  • disease activity
  • interstitial lung disease
  • ankylosing spondylitis